Search

Your search keyword '"Kotoula, Vassiliki"' showing total 569 results
Start Over Author "Kotoula, Vassiliki"
569 results on '"Kotoula, Vassiliki"'

52. In VitroandIn VivoAnticancer Effects of Metformin and the AMP-Activated Protein Kinase (AMPK) Activator 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside (AICAR): Enhanced Activity in the Presence of the Local Microenvironment, Activated Akt/mTOR Pathway and Exposure to Glycolysis Inhibitors.

Author

Ooi, Melissa, primary, McMillin, Douglas W., additional, Kotoula, Vassiliki, additional, Negri, Joseph, additional, Delmore, Jake, additional, Mitsiades, Constantine S., additional, Anderson, Kenneth C., additional, and Mitsiades, Nicholas, additional

Published
2010
Full Text
View/download PDF

53. Is There an Independent Role of TERT and NF1 in High Grade Gliomas?

Author

Razis, Evangelia, primary, Kotoula, Vassiliki, additional, Koliou, Georgia-Angeliki, additional, Papadopoulou, Kyriaki, additional, Vrettou, Eleni, additional, Giannoulatou, Eleni, additional, Tikas, Ioannis, additional, Labropoulos, Stefanos V., additional, Rigakos, Georgios, additional, Papaemmanoyil, Styliani, additional, Romanidou, Ourania, additional, Bourkoula, Eugenia, additional, Nomikos, Panagiotis, additional, Iliadis, Georgios, additional, Nasioulas, George, additional, Selviaridis, Panagiotis, additional, Polyzoidis, Konstantinos, additional, and Fountzilas, George, additional

Published
2020
Full Text
View/download PDF

54. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative

Author

Fountzilas, Elena, primary, Kotoula, Vassiliki, additional, Koliou, Georgia-Angeliki, additional, Giannoulatou, Eleni, additional, Gogas, Helen, additional, Papadimitriou, Christos, additional, Tikas, Ioannis, additional, Zhang, Jianhua, additional, Papadopoulou, Kyriaki, additional, Zagouri, Flora, additional, Christodoulou, Christos, additional, Koutras, Angelos, additional, Makatsoris, Thomas, additional, Chrisafi, Sofia, additional, Linardou, Helena, additional, Varthalitis, Ioannis, additional, Papatsibas, George, additional, Razis, Evangelia, additional, Papakostas, Pavlos, additional, Samantas, Epaminontas, additional, Aravantinos, Gerasimos, additional, Bafaloukos, Dimitrios, additional, Kosmidis, Paris, additional, Koumarianou, Anna, additional, Psyrri, Amanda, additional, Pentheroudakis, Georgios, additional, Pectasides, Dimitrios, additional, Futreal, Andrew, additional, Fountzilas, George, additional, and Tsimberidou, Apostolia M., additional

Published
2020
Full Text
View/download PDF

55. Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer

Author

NIKOLAIDI, ADAMANTIA, primary, KOTOULA, VASSILIKI, additional, KOLIOU, GEORGIA-ANGELIKI, additional, GIANNOULATOU, ELENI, additional, PAPADOPOULOU, KYRIAKI, additional, ZAGOURI, FLORA, additional, PENTHEROUDAKIS, GEORGE, additional, GOGAS, HELEN, additional, BOBOS, MATTHEOS, additional, CHATZOPOULOS, KYRIAKOS, additional, OIKONOMOPOULOS, GEORGIOS, additional, PECTASIDES, DIMITRIOS, additional, SALOUSTROS, EMMANOUIL, additional, ARNOGIANNAKI, NIKI, additional, NICOLAOU, IRENE, additional, PAPAKOSTAS, PAVLOS, additional, BOMPOLAKI, ILIADA, additional, ARAVANTINOS, GERASIMOS, additional, ATHANASIADIS, ILIAS, additional, and FOUNTZILAS, GEORGE, additional

Published
2020
Full Text
View/download PDF

57. Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy

Author

PECTASIDES, EIRINI, primary, CHATZIDAKIS, IOANNIS, additional, KOTOULA, VASSILIKI, additional, KOLIOU, GEORGIA-ANGELIKI, additional, PAPADOPOULOU, KYRIAKI, additional, GIANNOULATOU, ELENI, additional, GIANNOUZAKOS, VASILIOS G., additional, BOBOS, MATTHEOS, additional, PAPAVASILEIOU, CHRISTOS, additional, CHRISAFI, SOFIA, additional, FLOROU, AIKATERINI, additional, PECTASIDES, DIMITRIOS, additional, and FOUNTZILAS, GEORGE, additional

Published
2020
Full Text
View/download PDF

58. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab

Author

Pentheroudakis, George, primary, Mavroeidis, Leonidas, additional, Papadopoulou, Kyriaki, additional, Koliou, Georgia-Angeliki, additional, Bamia, Christina, additional, Chatzopoulos, Kyriakos, additional, Samantas, Epaminontas, additional, Mauri, Davide, additional, Efstratiou, Ioannis, additional, Pectasides, Dimitrios, additional, Makatsoris, Thomas, additional, Bafaloukos, Dimitrios, additional, Papakostas, Pavlos, additional, Papatsibas, George, additional, Bombolaki, Iliada, additional, Chrisafi, Sofia, additional, Kourea, Helen P., additional, Petraki, Kalliopi, additional, Kafiri, Georgia, additional, Fountzilas, George, additional, and Kotoula, Vassiliki, additional

Published
2019
Full Text
View/download PDF

60. The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Author

Strimpakos, Alexios, Pentheroudakis, George, Kotoula, Vassiliki, De Roock, Wendy, Kouvatseas, George, Papakostas, Pavlos, Makatsoris, Thomas, Papamichael, Demetris, Andreadou, Anna, Sgouros, Joseph, Zizi-Sermpetzoglou, Adamantia, Kominea, Athina, Televantou, Despina, Razis, Evangelia, Galani, Eleni, Pectasides, Dimitrios, Tejpar, Sabine, Syrigos, Konstantinos, and Fountzilas, George

Published
2013
Full Text
View/download PDF

64. Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment

Author

Linardou, Helena Kotoula, Vassiliki Kouvatseas, George and Mountzios, Giannis Karavasilis, Vasilios Samantas, Epaminondas and Kalogera-Fountzila, Anna Televantou, Despina Papadopoulou, Kyriaki Mavropoulou, Xanthipi Daskalaki, Emily Zaramboukas, Thomas Efstratiou, Ioannis Lampaki, Sofia Rallis, Grigorios and Res, Eleni Syrigos, Konstantinos N. Kosmidis, Paris A. and Pectasides, Dimitrios Fountzilas, George

Subjects
neoplasms, digestive system diseases, respiratory tract diseases
Abstract

Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. Results: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). Conclusion: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment.

Published
2019

72. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab

Author

Fountzilas George, Christodoulou Christos, Bobos Mattheos, Kotoula Vassiliki, Eleftheraki Anastasia G, Xanthakis Ioannis, Batistatou Anna, Pentheroudakis George, Xiros Nikolaos, Papaspirou Irene, Koumarianou Anna, Papakostas Pavlos, Bafaloukos Dimitrios, Skarlos Dimosthenis V, and Kalogeras Konstantine T

Subjects
Breast cancer, Topoisomerase II alpha, Fluorescence in situ hybridization, Gene amplification, Trastuzumab, Prognostic factors, Anthracyclines, Predictive factors, Medicine
Abstract

Abstract Background The vast majority of patients with HER2-positive metastatic breast cancer (MBC) treated with trastuzumab eventually develop resistance to this agent. There is an unmet need therefore, for identifying biological markers with possible prognostic/predictive value in such patients. The aim of this study was to investigate the prognostic role of topoisomerase II alpha gene (TOP2A) amplification and protein (TopoIIa) expression in patients treated with trastuzumab-containing regimens. Methods Formalin-fixed paraffin-embedded tumor tissue samples were retrospectively collected from 225 eligible patients treated with trastuzumab. Protein expression of ER, PgR, Ki67, PTEN, HER2 and TopoIIa were centrally assessed by immunohistochemistry. HER2 and TOP2A gene amplification was evaluated by fluorescence in situ hybridization. PIK3CA mutations were identified by single nucleotide polymorphism genotyping. Survival was evaluated from the initiation of trastuzumab as 1st line treatment to the date of last follow-up or death. Results Among the 225 samples analyzed, only 137 (61%) were found to be HER2-positive. TOP2A was amplified in 41% and deleted in 16% of such tumors. TOP2A gene amplification was more frequent in ER-negative tumors. TopoIIa protein expression was observed in the majority (65%) of the samples and was associated with ER-positive status, high Ki67 expression, presence of PTEN protein and PIK3CA mutations. Median follow-up for patients treated in the 1st line was 51 months. Survival was more prolonged with trastuzumab-containing treatment in HER2-positive patients (50 months, log-rank, p=0.007). TOP2A non-amplified or deleted tumors were associated with increased risk for death compared to TOP2A amplified tumors (HR=2.16, Wald’s p=0.010 and HR=2.67, p=0.009, respectively). In multivariate analysis, a significant interaction of TOP2A with anthracycline treatment (either in the adjuvant or the 1st line setting) was observed for survival (Wald’s p=0.015). Among the TOP2A amplified subgroup, anthracycline-treated patients were associated with decreased risk for death. Conclusions TOP2A gene amplification was shown to be a favorable prognostic marker in HER2-positive MBC patients treated with trastuzumab, such an effect however, appears to rather be related to treatment with anthracyclines (predictive marker for benefit from anthracyclines). The results of the present retrospective study warrant validation in larger cohorts of patients treated in the context of randomized trials.

Published
2012
Full Text
View/download PDF

73. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)

Author

Kotoula Vassiliki, Krikelis Dimitrios, Karavasilis Vasilios, Koletsa Triantafillia, Eleftheraki Anastasia G, Televantou Despina, Christodoulou Christos, Dimoudis Stefanos, Korantzis Ippokratis, Pectasides Dimitrios, Syrigos Konstantinos N, Kosmidis Paris A, and Fountzilas George

Subjects
NSCLC, ERCC1, TYMS, mRNA, Predictive, Normal lung, FFPE, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background BRCA1 (B), ERCC1 (E), RRM1 (R) and TYMS (T) mRNA expression has been extensively studied with respect to NSCLC patient outcome upon various chemotherapy agents. However, these markers have not been introduced into clinical practice yet. One of the reasons seems to be lack of a standard approach for the classification of the reported high/low mRNA expression. The aim of this study was to determine the prognostic/predictive impact of B, E, R, T in routinely-treated NSCLC patients by taking into account the expression of these genes in the normal lung parenchyma. Methods B, E, R, T mRNA expression was examined in 276 NSCLC samples (real-time PCR). The normal range of B, E, R, T transcript levels was first determined in matched tumor – normal pairs and then applied to the entire tumor series. Four main chemotherapy categories were examined: taxanes-without-platinum (Tax); platinum-without-taxanes (Plat); taxanes/platinum doublets (Tax/Plat); and, all-other combinations. Results In comparison to remotely located normal lung parenchyma, B, E, R, T mRNA expression was generally increased in matched tumors, as well as in the entire tumor series. Therefore, tumors were classified as expressing normal or aberrant B, E, R, T mRNA. In general, no marker was associated with overall and progression free survival (OS, PFS). Upon multivariate analysis, aberrant intratumoral TYMS predicted for shorter PFS than normal TYMS in 1st line chemo-naïve treated patients (p = 0.012). In the same setting, specific interactions were observed for aberrant TYMS with Plat and Tax/Plat (p = 0.003 and p = 0.006, respectively). Corresponding patients had longer PFS in comparison to those treated with Tax (Plat: HR = 0.234, 95% CI:0.108-0.506, Wald’s p Conclusion Classifying intratumoral B, E, R, T mRNA expression in comparison to normal lung may facilitate standardization of these parameters for prospective studies. With this approach, NSCLC patients with aberrant intratumoral TYMS expression will probably fare better with platinum-based treatments.

Published
2012
Full Text
View/download PDF

74. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

Author

Fountzilas George, Valavanis Christos, Kotoula Vassiliki, Eleftheraki Anastasia G, Kalogeras Konstantine T, Tzaida Olympia, Batistatou Anna, Kronenwett Ralf, Wirtz Ralph M, Bobos Mattheos, Timotheadou Eleni, Soupos Nikolaos, Pentheroudakis George, Gogas Helen, Vlachodimitropoulos Dimitrios, Polychronidou Genovefa, Aravantinos Gerasimos, Koutras Angelos, Christodoulou Christos, Pectasides Dimitrios, and Arapantoni Petroula

Subjects
HER2, TOP2A, gene amplification, CISH, mRNA expression, early breast cancer, randomized study, anthracyclines, taxanes, Medicine
Abstract

Abstract Background HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk breast cancer patients treated with epirubicin-based, dose-dense sequential adjuvant chemotherapy. Methods In a series of 352 breast carcinoma tissues from patients that had been post-operatively treated with epirubicin-CMF with or without paclitaxel, we assessed HER2 and TOP2A gene status (chromogenic in situ hybridization), mRNA expression (quantitative reverse transcription PCR), as well as HER2 and TopoIIa protein expression (immunohistochemistry). Results HER2 and TOP2A amplification did not share the same effects on their downstream molecules, with consistent patterns observed in HER2 mRNA and protein expression according to HER2 amplification (all parameters strongly inter-related, p values < 0.001), but inconsistent patterns in the case of TOP2A. TOP2A gene amplification (7% of all cases) was not related to TOP2A mRNA and TopoIIa protein expression, while TOP2A mRNA and TopoIIa protein were strongly related to each other (p < 0.001). Hence, TOP2A amplified tumors did not correspond to tumors with high TOP2A mRNA or TopoIIa protein expression, while the latter were characterized by high Ki67 scores (p = 0.003 and p < 0.001, respectively). Multivariate analysis adjusted for nodal involvement, hormone receptor status, Ki67 score and HER2/TOP2A parameters revealed HER2/TOP2A co-amplification (21.2% of HER2 amplified tumors) as an independent favorable prognostic factor for DFS (HR = 0.13, 95% CI: 0.02-0.96, p = 0.046); in contrast, increased HER2/TOP2A mRNA co-expression was identified as an independent adverse prognostic factor for both DFS (HR = 2.41, 95% CI: 1.31-4.42, p = 0.005) and OS (HR = 2.83, 95% CI: 1.42-5.63, p = 0.003), while high TOP2A mRNA expression was an independent adverse prognostic factor for OS (HR = 2.06, 95% CI: 1.23-3.46, p = 0.006). None of the parameters tested was associated with response to paclitaxel. Conclusions This study confirms the favorable prognostic value of HER2/TOP2A co-amplification and the adverse prognostic value of high TOP2A mRNA expression extending it to the adjuvant treatment setting in early high-risk breast cancer. The strong adverse prognostic impact of high HER2/TOP2A mRNA co-expression needs further validation in studies designed to evaluate markers predictive for anthracyclines. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12611000506998.

Published
2012
Full Text
View/download PDF

75. Volumetric and MGMT parameters in glioblastoma patients: Survival analysis

Author

Iliadis Georgios, Kotoula Vassiliki, Chatzisotiriou Athanasios, Televantou Despina, Eleftheraki Anastasia G, Lambaki Sofia, Misailidou Despina, Selviaridis Panagiotis, and Fountzilas George

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background In this study several tumor-related volumes were assessed by means of a computer-based application and a survival analysis was conducted to evaluate the prognostic significance of pre- and postoperative volumetric data in patients harboring glioblastomas. In addition, MGMT (O6-methylguanine methyltransferase) related parameters were compared with those of volumetry in order to observe possible relevance of this molecule in tumor development. Methods We prospectively analyzed 65 patients suffering from glioblastoma (GBM) who underwent radiotherapy with concomitant adjuvant temozolomide. For the purpose of volumetry T1 and T2-weighted magnetic resonance (MR) sequences were used, acquired both pre- and postoperatively (pre-radiochemotherapy). The volumes measured on preoperative MR images were necrosis, enhancing tumor and edema (including the tumor) and on postoperative ones, net-enhancing tumor. Age, sex, performance status (PS) and type of operation were also included in the multivariate analysis. MGMT was assessed for promoter methylation with Multiplex Ligation-dependent Probe Amplification (MLPA), for RNA expression with real time PCR, and for protein expression with immunohistochemistry in a total of 44 cases with available histologic material. Results In the multivariate analysis a negative impact was shown for pre-radiochemotherapy net-enhancing tumor on the overall survival (OS) (p = 0.023) and for preoperative necrosis on progression-free survival (PFS) (p = 0.030). Furthermore, the multivariate analysis confirmed the importance of PS in PFS and OS of patients. MGMT promoter methylation was observed in 13/23 (43.5%) evaluable tumors; complete methylation was observed in 3/13 methylated tumors only. High rate of MGMT protein positivity (> 20% positive neoplastic nuclei) was inversely associated with pre-operative tumor necrosis (p = 0.021). Conclusions Our findings implicate that volumetric parameters may have a significant role in the prognosis of GBM patients. Furthermore, volumetry could help not only to improve the prediction of outcome but also the outcome itself by identifying patients at high risk of treatment failure and, thus, seek alternative treatment for these patients. In this small series, MGMT protein was associated with less aggressive tumor characteristics.

Published
2012
Full Text
View/download PDF

76. Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

Author

Fountzilas, Elena Levva, Sofia Mountzios, Giannis and Polychronidou, Genovefa Maniadakis, Nikos Kotoula, Vassiliki and Fountzilas, George

Abstract

Purpose Because of the profound financial crisis that commenced in Greece in 2010, severe cuts in health care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non-small-cell lung cancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center in Greece throughout the period of financial crisis. Patients and Methods From 2011 through 2015, 252 patients with newly diagnosed advanced NSCLC were treated at the Department of Medical Oncology of the Papageorgiou Hospital, a tertiary cancer center in northern Greece. We retrospectively reviewed patient medical records to obtain clinicopathologic characteristics, EGFR mutation status, and follow-up data. The primary end point was time to treatment failure. Results Of the 198 evaluable patients, 25 (12%) had EGFR mutations. All patients with EGFR mutations except one received treatment with an EGFR tyrosine kinase inhibitor. Median times to treatment failure for patients with EGFR-mutant and wild-type disease were 15.8 and 7.1 months, respectively (hazard ratio, 0.58; 95% CI, 0.35 to 0.95; P = .031). There was no difference in overall survival between the two groups (P = .293). No deviation from treatment guidelines or discontinuation of treatment regimens occurred because of logistic reasons or drug shortages. Conclusion Despite restrictions in the reimbursement policy and accompanying controls in the use of high-cost medicines, the national program enabled treatment of patients with EGFR-mutant NSCLC according to established guidelines. Therefore, the clinical outcomes of such patients treated in Greece during the economic crisis were in accordance with international standards. (C) 2018 by American Society of Clinical Oncology

Published
2018

77. Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers

Author

Papadopoulou, Kyriaki, Murray, Samuel, Manousou, Kyriaki, Tikas, Ioannis, Dervenis, Christos, Sgouros, Joseph, Rontogianni, Dimitra, Lakis, Sotirios, Bobos, Mattheos, Poulios, Christos, Pervana, Stavroula, Lazaridis, Georgios, Fountzilas, George, and Kotoula, Vassiliki

Subjects
Original Article
Abstract

Biliary tract cancer (BTC) represents a heterogeneous disease with dismal outcome. Herein, we examined genotype and angiogenesis features in BTC. We applied genotyping (Sanger, qPCR, 101-gene panel NGS), mRNA relative quantification methods, and β-catenin immunohistochemistry in 84 FFPE BTC (55 gallbladder [GBC], 14 intrahepatic [ICC], 15 extrahepatic [ECC] carcinomas). We identified 541 mutations in 68 (81%) tumors. Top mutated genes were CTNNB1 (36%); PTEN (33%); TP53 (31%); PIK3R1 (29%); PIK3CA (13%); BRCA2 and KRAS (12%); BRCA1 (11%). Six GBCs were hypermutated [hm] displaying a distinct mutational pattern. Mutations in TP53 and PI3K, Wnt and RAS components were prevalent among non-hypermutated tumors. All hmGBCs carried mutations in BRCA2 and other homologous recombination repair (HRR) genes, in PD1, but not in CTNNB1 and KRAS. None of the pathogenic BRCA2 p.D2723G and BRCA1 p.Q563* and c.5266dupC was present at frequencies expected for germline mutations. We observed copy gains (>6 copies) in EGFR (9% of informative tumors), PRKAR1A (7%), PIK3CA (6%), ERBB2 (5%) and MET (4%). TP53 mutations were prevalent in GBC (P

Published
2018

78. Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma

Author

Chatzopoulos, Kyriakos, primary, Kotoula, Vassiliki, additional, Manoussou, Kyriaki, additional, Markou, Konstantinos, additional, Vlachtsis, Konstantinos, additional, Angouridakis, Nikolaos, additional, Nikolaou, Angelos, additional, Vassilakopoulou, Maria, additional, Psyrri, Amanda, additional, and Fountzilas, Georgios, additional

Published
2019
Full Text
View/download PDF

79. Abstract 486: Pathogenic drivers and their comutations in genes frequently altered in cancer

Author

Kotoula, Vassiliki, primary, Fountzilas, Elena, additional, Koliou, Georgia-Angeliki, additional, Papadopoulou, Kyriaki, additional, Giannoulatou, Eleni, additional, Tikas, Ioannis, additional, Zagouri, Flora, additional, Christodoulou, Christos, additional, Pentheroudakis, Georgios, additional, Koutras, Angelos, additional, Pectasides, Dimitrios, additional, and Fountzilas, George, additional

Published
2019
Full Text
View/download PDF

80. Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry

Author

Carvajal-Hausdorf, Daniel E., primary, Patsenker, Jonathan, additional, Stanton, Kelly P., additional, Villarroel-Espindola, Franz, additional, Esch, Amanda, additional, Montgomery, Ruth R., additional, Psyrri, Amanda, additional, Kalogeras, Konstantine T., additional, Kotoula, Vassiliki, additional, Foutzilas, George, additional, Schalper, Kurt A., additional, Kluger, Yuval, additional, and Rimm, David L., additional

Published
2019
Full Text
View/download PDF

82. Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab

Author

Economopoulou, Panagiota, primary, Kotoula, Vassiliki, additional, Koliou, Georgia-Angeliki, additional, Papadopoulou, Kyriaki, additional, Christodoulou, Christos, additional, Pentheroudakis, George, additional, Lazaridis, Georgios, additional, Arapantoni-Dadioti, Petroula, additional, Koutras, Angelos, additional, Bafaloukos, Dimitris, additional, Papakostas, Pavlos, additional, Patsea, Helen, additional, Pavlakis, Kitty, additional, Pectasides, Dimitrios, additional, Kotsakis, Athanasios, additional, Razis, Evangelia, additional, Aravantinos, Gerasimos, additional, Samantas, Epaminondas, additional, Kalogeras, Konstantine T., additional, Economopoulos, Theofanis, additional, Psyrri, Amanta, additional, and Fountzilas, George, additional

Published
2019
Full Text
View/download PDF

83. Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer

Author

RALLIS, GRIGORIOS, primary, KOLETSA, TRIANTAFYLLIA, additional, SARIDAKI, ZENIA, additional, MANOUSOU, KYRIAKI, additional, KOLIOU, GEORGIA-ANGELIKI, additional, KOSTOPOULOS, IOANNIS, additional, KOTOULA, VASSILIKI, additional, MAKATSORIS, THOMAS, additional, KOUREA, HELEN P., additional, RAPTOU, GEORGIA, additional, CHRISAFI, SOFIA, additional, SAMANTAS, EPAMINONTAS, additional, PAPAPARASKEVA, KLEO, additional, PAZARLI, ELISSAVET, additional, PAPAKOSTAS, PAVLOS, additional, KAFIRI, GEORGIA, additional, MAURI, DAVIDE, additional, PAPOUDOU-BAI, ALEXANDRA, additional, CHRISTODOULOU, CHRISTOS, additional, PETRAKI, KALLIOPI, additional, DOMBROS, NIKOLAOS, additional, PECTASIDES, DIMITRIOS, additional, and FOUNTZILAS, GEORGE, additional

Published
2019
Full Text
View/download PDF

84. Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment

Author

LINARDOU, HELENA, primary, KOTOULA, VASSILIKI, additional, KOUVATSEAS, GEORGE, additional, MOUNTZIOS, GIANNIS, additional, KARAVASILIS, VASILIOS, additional, SAMANTAS, EPAMINONDAS, additional, KALOGERA-FOUNTZILA, ANNA, additional, TELEVANTOU, DESPINA, additional, PAPADOPOULOU, KYRIAKI, additional, MAVROPOULOU, XANTHIPI, additional, DASKALAKI, EMILY, additional, ZARAMBOUKAS, THOMAS, additional, EFSTRATIOU, IOANNIS, additional, LAMPAKI, SOFIA, additional, RALLIS, GRIGORIOS, additional, RES, ELENI, additional, SYRIGOS, KONSTANTINOS N., additional, KOSMIDIS, PARIS A., additional, PECTASIDES, DIMITRIOS, additional, and FOUNTZILAS, GEORGE, additional

Published
2019
Full Text
View/download PDF

85. Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer

Author

LAZARIDIS, GEORGIOS, primary, KOTOULA, VASSILIKI, additional, VRETTOU, ELENI, additional, KOSTOPOULOS, IOANNIS, additional, MANOUSOU, KYRIAKI, additional, PAPADOPOULOU, KYRIAKI, additional, GIANNOULATOU, ELENI, additional, BOBOS, MATTHEOS, additional, SOTIROPOULOU, MARIA, additional, PENTHEROUDAKIS, GEORGE, additional, EFSTRATIOU, IOANNIS, additional, PAPOUDOU-BAI, ALEXANDRA, additional, PSYRRI, AMANDA, additional, CHRISTODOULOU, CHRISTOS, additional, GOGAS, HELEN, additional, KOUTRAS, ANGELOS, additional, TIMOTHEADOU, ELENI, additional, PECTASIDES, DIMITRIOS, additional, ZAGOURI, FLORA, additional, and FOUNTZILAS, GEORGE, additional

Published
2019
Full Text
View/download PDF

87. Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer

Author

Polychronidou, Genovefa, primary, Kotoula, Vassiliki, additional, Manousou, Kyriaki, additional, Kostopoulos, Ioannis, additional, Karayannopoulou, Georgia, additional, Vrettou, Eleni, additional, Bobos, Mattheos, additional, Raptou, Georgia, additional, Efstratiou, Ioannis, additional, Dionysopoulos, Dimitrios, additional, Chatzopoulos, Kyriakos, additional, Lakis, Sotirios, additional, Chrisafi, Sofia, additional, Tsolakidis, Dimitrios, additional, Papanikolaou, Alexios, additional, Dombros, Nikolaos, additional, and Fountzilas, George, additional

Published
2018
Full Text
View/download PDF

88. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study

Author

Koutras, Angelos, primary, Lazaridis, Georgios, additional, Koliou, Georgia-Angeliki, additional, Kouvatseas, George, additional, Christodoulou, Christos, additional, Pectasides, Dimitrios, additional, Kotoula, Vassiliki, additional, Batistatou, Anna, additional, Bobos, Mattheos, additional, Tsolaki, Eleftheria, additional, Papadopoulou, Kyriaki, additional, Pentheroudakis, George, additional, Papakostas, Pavlos, additional, Pervana, Stavroula, additional, Petraki, Kalliopi, additional, Chrisafi, Sofia, additional, Razis, Evangelia, additional, Psyrri, Amanda, additional, Bafaloukos, Dimitrios, additional, Kalogeras, Konstantine T., additional, Kalofonos, Haralambos P., additional, and Fountzilas, George, additional

Published
2018
Full Text
View/download PDF

89. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer

Author

Pentheroudakis, George, primary, Kotoula, Vassiliki, additional, Koliou, Georgia-Angeliki, additional, Karavasilis, Vasilios, additional, Samantas, Epaminontas, additional, Aravantinos, Gerasimos, additional, Kalogeropoulou, Lydia, additional, Souglakos, Ioannis, additional, Kentepozidis, Nikolaos, additional, Koumakis, Georgios, additional, Sgouros, Joseph, additional, Zarkavelis, Georgios, additional, Efstratiou, Ioannis, additional, Laschos, Konstantinos, additional, Petraki, Constantina, additional, Tikas, Ioannis, additional, Poulios, Christos, additional, Voutsina, Alexandra, additional, Goudopoulou, Athina, additional, Bafaloukos, Dimitrios, additional, Vrettou, Eleni, additional, Kalogera-Fountzila, Anna, additional, Pectasides, Dimitrios, additional, and Fountzilas, George, additional

Published
2018
Full Text
View/download PDF

91. Telomerase activity in precancerous hepatic nodules

Author

Hytiroglou, Prodromos, Kotoula, Vassiliki, Thung, Swan N., Tsokos, Maria, Fiel, M. Isabel, and Papadimitriou, Constantine S.

Subjects
Reverse transcriptase -- Analysis, Cell transformation -- Physiological aspects, Liver cirrhosis -- Development and progression, Telomerase -- Research, Health
Published
1998

92. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data

Author

Zardavas, Dimitrios, te Marvelde, Luc, Milne, Roger L., Fumagalli, Debora, Fountzilas, George, Kotoula, Vassiliki, Razis, Evangelia, Papaxoinis, George, Joensuu, Heikki, Moynahan, Mary Ellen, Hennessy, Bryan T., Bieche, Ivan, Saal, Lao H., Stål, Olle, Iacopetta, Barry, Jensen, Jeanette Dupont, OToole, Sandra, Lopez-Knowles, Elena, Barbaraeschi, Mattia, Noguchi, Shinzaburo, Azim, Hatem A. Jr., Lerma, Enrique, Bachelot, Thomas, Wang, Qing, Perez Tenorio, Gizeh, de Velde, Cornelis J. H. Can, Rea, Daniel W., Sabine, Vicky, Bartlett, John M. S., Sotiriou, Christos, Michiels, Stefan, Loi, Sherene, Zardavas, Dimitrios, te Marvelde, Luc, Milne, Roger L., Fumagalli, Debora, Fountzilas, George, Kotoula, Vassiliki, Razis, Evangelia, Papaxoinis, George, Joensuu, Heikki, Moynahan, Mary Ellen, Hennessy, Bryan T., Bieche, Ivan, Saal, Lao H., Stål, Olle, Iacopetta, Barry, Jensen, Jeanette Dupont, OToole, Sandra, Lopez-Knowles, Elena, Barbaraeschi, Mattia, Noguchi, Shinzaburo, Azim, Hatem A. Jr., Lerma, Enrique, Bachelot, Thomas, Wang, Qing, Perez Tenorio, Gizeh, de Velde, Cornelis J. H. Can, Rea, Daniel W., Sabine, Vicky, Bartlett, John M. S., Sotiriou, Christos, Michiels, Stefan, and Loi, Sherene

Abstract

PurposePhosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data.Patients and MethodsAssociations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall survival (OS) were also assessed, overall and by breast cancer subtypes.ResultsData from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787 patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%) received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations occurred in 32% of patients, with significant associations with ER positivity, increasing age, lower grade, and smaller size (all P amp;lt; .001). Prevalence of PIK3CA mutations was 18%, 22%, and 37% in the ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84; P amp;lt; .001), with evidence for a stronger effect in the first years of follow-up (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P amp;lt; .001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); amp;gt; 10 years: (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA genotype remained significant for improved IDFS (P = .043), but not for the DDFS and OS end points.ConclusionIn this large pooled analysis, PIK3CA mutations were significantly associated with a better IDFS, DDFS, and OS, but had a lesser prognostic eff, Funding Agencies|Cancer Council Victoria; National Health and Medical Research Council of Australia; National Breast Cancer Foundation, Australia; Breast Cancer Research Foundation, New York; Fonds de la Recherche Scientifique; Ontario Institute for Cancer Research; Government of Ontario; Trentino Biomolecular Oncologic Network (Trebionet) project; Swedish Research Council; Swedish Cancer Society

Published
2018
Full Text
View/download PDF

93. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: A pooled analysis of individual patient data

Author

Zardavas, Dimitros, Moynahan, Mary Ellen, Hennessy, Bryan B.T., Bieche, Ivan, Saal, Lao L.H., Stal, Olle, Iacopetta, Barry, Jensen, Jeanette Dupont, O'Toole, Sandra A, Lopez-Knowles, Elena, Barbaraeschi, Mattia, Te Marvelde, Luc, Noguchi, Shinzaburo, Abdel Azim, Hatem Hamdy, Lerma, Enrique, Bachelot, Thomas, Wang, Qing, Perez-Tenorio, Gizeh, Can De Velde, Cornelis C.J.H., Rea, Daniel William, Sabine, Vicky S, Bartlett, John, Milne, Roger R.L., Sotiriou, Christos, Michiels, Stefan, Loi, Sherene, Fumagalli, Debora, Fountzilas, George, Kotoula, Vassiliki, Razis, Evangelia, Papaxoinis, George, Joensuu, Heikki, Zardavas, Dimitros, Moynahan, Mary Ellen, Hennessy, Bryan B.T., Bieche, Ivan, Saal, Lao L.H., Stal, Olle, Iacopetta, Barry, Jensen, Jeanette Dupont, O'Toole, Sandra A, Lopez-Knowles, Elena, Barbaraeschi, Mattia, Te Marvelde, Luc, Noguchi, Shinzaburo, Abdel Azim, Hatem Hamdy, Lerma, Enrique, Bachelot, Thomas, Wang, Qing, Perez-Tenorio, Gizeh, Can De Velde, Cornelis C.J.H., Rea, Daniel William, Sabine, Vicky S, Bartlett, John, Milne, Roger R.L., Sotiriou, Christos, Michiels, Stefan, Loi, Sherene, Fumagalli, Debora, Fountzilas, George, Kotoula, Vassiliki, Razis, Evangelia, Papaxoinis, George, and Joensuu, Heikki

Abstract

Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall survival (OS) were also assessed, overall and by breast cancer subtypes. Results Data from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787 patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%) received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations occurred in 32% of patients, with significant associations with ER positivity, increasing age, lower grade, and smaller size (all P, 001). Prevalence of PIK3CA mutations was 18%, 22%, and 37% in the ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84; P, 001), with evidence for a stronger effect in the first years of follow-up (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P, 001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); 10 years: (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA genotype remained significant for improved IDFS (P = .043), but not for the DDFS and OS end points. Conclusion In this large pooled analysis, PIK3CA mutations were significantly associated with a better IDFS, DDFS, and OS, but had a lesser prognostic effect after adjustment for, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2018

95. Additional file 1: Table S1. of The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases

Author

Cohen, Stacey, Yu, Ming, Baker, Kelsey, Redman, Mary, Wu, Chen, Heinzerling, Tai, Wirtz, Ralph, Charalambous, Elpida, Pentheroudakis, George, Kotoula, Vassiliki, Kalogeras, Konstantine, Fountzilas, George, and Grady, William

Abstract

Amplicons targeting KRAS and BRAF, within the IAD47763_031 custom panel. (DOCX 17 kb)

Published
2017
Full Text
View/download PDF

97. Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer

Author

Fountzilas, Elena, primary, Kotoula, Vassiliki, additional, Tikas, Ioannis, additional, Manousou, Kyriaki, additional, Papadopoulou, Kyriaki, additional, Poulios, Christos, additional, Karavasilis, Vasilios, additional, Efstratiou, Ioannis, additional, Pectasides, Dimitrios, additional, Papaparaskeva, Kleo, additional, Varthalitis, Ioannis, additional, Christodoulou, Christos, additional, Papatsibas, George, additional, Chrisafi, Sofia, additional, Glantzounis, Georgios K., additional, Psyrri, Amanda, additional, Aravantinos, Gerasimos, additional, Koliou, Georgia-Angeliki, additional, Koukoulis, George K., additional, Pentheroudakis, George E., additional, and Fountzilas, George, additional

Published
2018
Full Text
View/download PDF

98. Abstract 1359: Somatic involution of pathogenic BRCA1 germline mutations

Author

Kotoula, Vassiliki, primary, Demiri, Efterpi, additional, Fostira, Florentia, additional, Vrettou, Eleni, additional, Papadopoulou, Kyriaki, additional, Tikas, Ioannis, additional, Papazisis, Konstantinos, additional, Zaramboukas, Thomas, additional, Asimaki-Vlachopoulou, Asimina, additional, Miliaras, Spyridon, additional, Fountzilas, Elena, additional, Ananiadis, Ananias, additional, Chrisafi, Sofia, additional, Poulios, Christos, additional, Natsiopoulos, Ioannis, additional, Tsiftsoglou, Aris, additional, and Fountzilas, George, additional

Published
2018
Full Text
View/download PDF

99. Clinical relevance of primary tumor site and respective molecular characteristics in patients with early-stage colorectal cancer.

Author

Fountzilas, Elena, primary, Kotoula, Vassiliki, additional, Tikas, Ioannis Sotirios, additional, Manousou, Kyriaki, additional, Papadopoulou, Kyriaki, additional, Poulios, Christos, additional, Karavasilis, Vasilios, additional, Efstratiou, Ioannis, additional, Pectasides, Dimitrios G., additional, Papaparaskeva, Kleo, additional, Varthalitis, Ioannis I., additional, Christodoulou, Christos, additional, Papatsibas, George, additional, Chrisafi, Sofia, additional, Glantzounis, Georgios K., additional, Psyrri, Amanda, additional, Aravantinos, Gerasimos, additional, Koukoulis, George K., additional, Pentheroudakis, George E., additional, and Fountzilas, George, additional

Published
2018
Full Text
View/download PDF

100. Evaluation of the significance of TERT mutations in the presence of NF1 mutations in high grade glioma.

Author

Razis, Evangelia, primary, Kotoula, Vassiliki, additional, Koliou, Georgia-Angeliki, additional, Vrettou, Eleni, additional, Giannoulatou, Eleni, additional, Tikas, Ioannis Sotirios, additional, Labropoulos, Stefanos V., additional, Papadopoulou, Kyriaki, additional, Rigakos, Georgios, additional, Papaemmanoyil, Styliani, additional, Romanidou, Ourania, additional, Nomikos, Panagiotis, additional, Iliadis, Georgios, additional, Selviaridis, Panagiotis, additional, Polyzoidis, Konstantinos, additional, and Fountzilas, George, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results